Drug Trial Radar · NCT07615660
Clinical Study of CVL006 Combination With 9MW2821
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
May 15, 2026
Primary completion
Apr 30, 2029
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Convalife (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with 9MW821 patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
CVL006 in combination with 9MW2821Drug
CVL006 in combination with 9MW2821
CVL006 in combination with 9MW2821Drug
CVL006 in combination with 9MW2821
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome MeasureTime frame: From date of randomization until the date of first documented progression, assessed up to 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.